1

Table S2 AFLIBERCEPT
Phase of Clinical Trial / Primary Site / Dosing Regimen / Adverse Event / Total Patients N / Patients Affected
N (%) / Reference
Phase 2 / Ovarian cancer / Aflibercept 2 mg/kg / Dysphonia / 106 / 39 (37) / NCT00327171
Aflibercept 4 mg/kg / 109 / 46 (42)
Phase 2 / NSCLC stage IV / Aflibercept 4 mg/kg / Dysphonia / 96 / 27 (28) / NCT00284141
Phase 2 / Ovarian cancer / Aflibercept 4 mg/kg / Dysphonia / 16 / 3 (19) / NCT00396591
Phase 2/3 / Ovarian cancer / Placebo / Dysphonia / 25 / 1 (4) / NCT00327444
Aflibercept 4 mg/kg / 30 / 7 (23)
Phase 3 / CRC stage IV VELOUR Trial / Folfiri + Placebo / Dysphonia / 605 / 20 (3) / NCT00561470
Folfiri + Aflibercept 4 mg/kg / 611 / 155 (25)
Phase 3 / NSCLC VITAL Trial / Docetaxel + placebo / Dysphonia / 453 / 16 (4) / NCT00532155
Aflibercept 4 mg/kg+ Docetaxel / 452 / 83 (18)
Phase 3 / Pancreas stage IV VANILLA Trial / Gemcitabine + Placebo / Dysphonia / 271 / 6 (2) / NCT00574275
Aflibercept 4 mg/kg + Gemcitabine / 270 / 40 (15)

Abbreviations: CRC, Colorectal Cancer; NSCLC, Non Small Cell Lung Cancer; FOLFIRI, 5-FU, leucoveorin, irinotecan.